STUDY

Skyrizi cleared psoriasis in far more people than Humira (72% vs 47%)

“Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.” Reich K et al. The Lancet. August 2019

Reich K et al. · The Lancet · August 2019

Phase 3 randomized controlled trial
The finding

At week 16, 72% on risankizumab and 47% on adalimumab reached at least a 90% improvement on the psoriasis score.

Type of study

Where this study sits on the evidence spectrum

Some kinds of studies are much more reliable than others. Studies further right do more to rule out chance and bias.

Weaker evidenceStronger evidence
Lab or animal studyCase reportCase seriesCohort studyRandomized trialMeta-analysis
Randomized and double-blind. During the initial comparison, neither participants nor investigators knew which biologic had been assigned.
At a glance

Who was studied and for how long

Randomized
605 adults
66 clinics in 11 countries
Main comparison
16 weeks
Followed by a switch phase
Condition
Moderate to severe psoriasis
Adults with chronic plaque psoriasis
Compared
Two biologics
Risankizumab vs adalimumab
What they did

How the study worked

605 adultsplaque psoriasisRANDOMSPLITRisankizumab301 assigned150 mg at weeks 0 and 4Adalimumab304 assigned80 mg starting doseMEASURED ATWeek 16main comparison605 adultsplaque psoriasisRANDOMSPLITRisankizumab301 assigned · 150 mg at weeks 0 and 4Adalimumab304 assigned · 80 mg starting doseMEASURED ATWeek 16main comparison
Random assignment301 adults received risankizumab and 304 received adalimumab.
Different schedulesRisankizumab was given at weeks 0 and 4. After a starting dose, adalimumab was given every two weeks beginning at week 1.
Switch phaseAt week 16, people who had a partial response to adalimumab were randomly assigned to switch or stay on it.
What they found

The results

RisankizumabAdalimumab

At least 90% improvement at week 16

Share reaching PASI 90 in the initial randomized comparison.

Risankizumab
72%
Adalimumab
47%
p < 0.0001

At least 90% improvement at week 44

Only people with a partial response to adalimumab at week 16 entered this comparison.

Switched to risankizumab
66%
Stayed on adalimumab
21%
p < 0.0001
The first result compares the original randomized groups. The second answers a different question: whether switching helped people whose psoriasis had partly improved on adalimumab. It does not apply to everyone who starts adalimumab.
Who paid for it

Funding and conflicts of interest

AbbVie and Boehringer Ingelheim funded the study.

How much to trust it

Strengths and limits

Strengths

  • Large, double-blind comparison with an active treatment
  • Directly tested a treatment switch in partial responders
  • Included clinics in 11 countries

Limits

  • The main comparison was at week 16
  • Only adults with moderate to severe plaque psoriasis were studied
  • The switch comparison involved 109 selected partial responders
  • The trial cannot reliably compare rare or long-term harms
High confidence in the week 16 skin result. The large blinded comparison supports a difference in clearance, but it cannot settle long-term safety.
What it means for you

The takeaway

More skin clearance

More people reached a 90% drop in their psoriasis score on risankizumab. Among partial responders to adalimumab, more reached that goal after switching than after staying on it.

These results are about skin response and do not compare effects on joint symptoms.

Pages that cite this study

Read more on Dermapedia

Terms in this study

Words worth knowing

PASI

A score that combines how much skin is affected with the redness, thickness and scaling of psoriasis patches.

PASI 90

At least a 90% drop in the PASI score.

Biologic

A medicine that targets a particular part of the immune system.

Original source

Reich K, Gooderham M, Thaçi D, Crowley JJ, Ryan C, Krueger JG, Tsai TF, Flack M, Gu Y, Williams DA, Thompson EHZ, Paul C. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.. Lancet. 2019;394(10198):576-586.

PMID 31280967